MedTrace Logo

Neoadjuvant Treatment of Breast Cancer

NCT05131893 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-11-23

No results posted yet for this study

Summary

Observational investigation of participants who are given neoadjuvant treatment for invasive breast cancer. The scope of the study is to collect information on standardized treatment results, to explore the causes of dose modification and its effect on efficacy, to explore potential prognostic factors, and to explore the long-term side effects of different treatment modalities.

Conditions

Interventions

DRUG

Tamoxifen

endocrine therapy

DRUG

Goserelin

endocrine therapy

DRUG

Letrozole 2.5Mg Tab

endocrine therapy

DRUG

Epirubicin

chemotherapy

DRUG

cyclophosphamide

chemotherapy

DRUG

Docetaxel

chemotherapy

DRUG

paclitaxel

chemotherapy

DRUG

trastuzumab

biological treatment

DRUG

pertuzumab

biological treatment

DRUG

Capecitabine

chemotherapy

Sponsors & Collaborators

  • National Institute of Oncology, Hungary

    lead OTHER

Principal Investigators

  • Gabor Rubovszky · NIO Hungary

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2023-03-31
Completion
2031-12-31
FDA Drug
Yes

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05131893 on ClinicalTrials.gov